Halozyme Therapeutics Inc (NASDAQ:HALO)
| 32.18 Delayed Data As of Dec 01 |  -0.70 / -2.13%Today’s Change | 32.16 Today|||52-Week Range 56.40 | -24.65% Year-to-Date |
Latest HALO News | Press Releases
No recent news for Halozyme Therapeutics Inc.
Today’s Trading
| Previous close | 32.88 |
| Today’s open | 33.76 |
| Day’s range | 32.18 - 33.63 |
| Volume | 69,685 |
| Average volume (3 months) | 770,405 |
| Market cap | $4.8B |
Data as of 4:00pm ET, 12/01/2021
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +189.51% |
| Earnings growth (next 5 years) | +41.00% |
| Revenue growth (last year) | +36.53% |
| P/E ratio | 11.5 |
| Price/Sales | 22.58 |
| Price/Book | 30.26 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TLRYTilray Inc | -0.86 | -8.50% |
| TWSTTwist Bioscience Cor... | -8.37 | -8.76% |
| KODKodiak Sciences Inc | -3.72 | -4.05% |
| ---- |
Data as of 4:49pm ET, 12/01/2021
Financials
| Next reporting date | February 28, 2022 |
| EPS forecast (this quarter) | $0.40 |
| Annual revenue (last year) | $267.6M |
| Annual profit (last year) | $129.1M |
| Net profit margin | 48.24% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters --, -- |
Forecasts
